Loading data for TARA — first visit, this takes a few seconds.

알림

Protara Therapeutics Inc. (TARA)

NasdaqGM: TARA · 실시간 가격 · USD

3.85

-0.05 (-1.28%)

종가 기준: Aug 21, 2026, 8:00 PM

3.98

+3.38%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-1.28% (1D)

데이터 없음

매수호가	2.92
시가총액	227.52M
매출 (ttm)	n/a
순이익 (ttm)	-70.02M
	1.49
	-1.36
	n/a
	-2.28
P/B (ttm)	1.17
P/S (ttm)	n/a
실적 발표일	Nov 10, 2026

매도호가	5.12
거래량	234,708
평균 거래량 (20일)	581,401
시가	3.92
전일 종가	3.90
일중 범위	3.81 - 3.95
52주 범위	3.02 - 7.82
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TARA 소개

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substra...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 22, 2014

직원 수 46

상장 거래소 NasdaqGM

티커 TARA

웹사이트 https://www.protaratx.com

전체 기업 정보

재무 실적

2025년 Protara Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -57.44M로, 28.8% 증가했습니다.

재무제표

어닝 서프라이즈

Protara Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.36 예상치 하회 -0.05, 및 -2.86% 전년 대비 감소.

다음 실적 발표

Protara Therapeutics Inc.의 실적 발표 예정일은 Nov 10, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Zacks

What Makes Protara Therapeutics (TARA) a New Buy Stock

Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2개월 전 · Motley Fool

Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million

Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials.

3개월 전 · Simply Wall St.

One Protara Therapeutics Insider Raised Their Stake In The Previous Year

From what we can see, insiders were net buyers in Protara Therapeutics, Inc.'s ( NASDAQ:TARA ) during the past 12...

5개월 전 · Associated Press Finance

Protara Therapeutics: Q4 Earnings Snapshot

NEW YORK (AP) — Protara Therapeutics, Inc. TARA) on Tuesday reported a loss of $17.3 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 37 cents.

5개월 전 · MarketBeat

Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf

Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company’s two clinical-stage programs during a fireside chat at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference...

2 페이지 중 1

Protara Therapeutics Inc. (TARA)